Literature DB >> 24839802

Palliative radiotherapy for prostate cancer.

Matthew J Boyer, Joseph K Salama, W Robert Lee.   

Abstract

Radiotherapy is an effective tool for the palliation of symptoms commonly caused by prostate cancer. The majority of painful bone metastases respond equally well to single or multiple fractions of external radiotherapy. Retreatment with a second course of radiation induces pain responses in approximately 50% of patients. For more diffuse metastases, either hemibody radiation or systemic radiopharmaceuticals can reduce pain, and radium-223 is associated with improved survival in men with castration-resistant prostate cancer. Hematuria, bladder outlet obstruction, and rectal compression are all improved with palliative radiotherapy. The ability of stereotactic body radiation therapy to reduce pain compared with standard external radiation is being investigated, as is its role in treating those with limited metastatic disease.

Entities:  

Mesh:

Year:  2014        PMID: 24839802

Source DB:  PubMed          Journal:  Oncology (Williston Park)        ISSN: 0890-9091            Impact factor:   2.990


  1 in total

1.  Radiotherapy cannot prolong overall survival of young prostate cancer patients with bone metastases.

Authors:  Bo Peng; Cheng Yang; Jian He
Journal:  J Transl Med       Date:  2016-04-27       Impact factor: 5.531

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.